Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
Neoadjuvant therapy is commonly used in patients with locally advanced or inoperable
breast cancer (BC). Neoadjuvant chemotherapy (NACT) represents an established …
breast cancer (BC). Neoadjuvant chemotherapy (NACT) represents an established …
Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer
F Cherifi, A Da Silva, D Martins-Branco… - Expert Opinion on …, 2024 - Taylor & Francis
Introduction Currently three antibody-drug-conjugates (ADC) are approved by the European
Medicines Agency (EMA) for treatment of breast cancer (BC) patient: trastuzumab …
Medicines Agency (EMA) for treatment of breast cancer (BC) patient: trastuzumab …
Clinical, Epidemiologic, and Pathologic Significance of ERBB2-Low Expression in Breast Cancer
Importance It is unclear whether breast cancer (BC) with low ERBB2 expression (ERBB2-
low) is a distinct clinical, pathological, and epidemiological entity from BC classified as no …
low) is a distinct clinical, pathological, and epidemiological entity from BC classified as no …
[HTML][HTML] Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression
NM Atallah, M Haque, C Quinn, MS Toss… - European Journal of …, 2023 - Elsevier
Background Breast cancer (BC) expressing low levels of human epidermal growth factor
receptor 2 (HER2 Low) is an emerging category that needs further refining. This study aims …
receptor 2 (HER2 Low) is an emerging category that needs further refining. This study aims …
[HTML][HTML] A population-based study on trajectories of HER2 status during neoadjuvant chemotherapy for early breast cancer and metastatic progression
C Boman, X Liu, L Eriksson Bergman, W Sun… - British Journal of …, 2024 - nature.com
Background This study aimed to investigate the distribution and changes of HER2 status in
untreated tumours, in residual disease and in metastasis, and their long-term prognostic …
untreated tumours, in residual disease and in metastasis, and their long-term prognostic …
[HTML][HTML] The association between HER2-low status and survival in patients with metastatic breast cancer treated with Cyclin-dependent kinases 4 and 6 inhibitors: a …
Purpose The cyclin-dependent kinase (CDK) 4/6 inhibitors significantly altered the treatment
landscape of hormone-positive (HR+), HER2-metastatic breast cancer (MBC). However …
landscape of hormone-positive (HR+), HER2-metastatic breast cancer (MBC). However …
[HTML][HTML] HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
X Baez-Navarro, NS van den Ende, AH Nguyen… - Breast Cancer …, 2024 - Springer
Most patients with triple-negative breast cancer (TNBC) are not candidates for targeted
therapy, leaving chemotherapy as the primary treatment option. Recently, immunotherapy …
therapy, leaving chemotherapy as the primary treatment option. Recently, immunotherapy …
Characterization of HER2‐low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort …
F Schettini, E Blondeaux, C Molinelli, R Bas, HJ Kim… - Cancer, 2024 - Wiley Online Library
Background Breast cancer (BC) in women aged≤ 40 years carrying germline pathogenetic
variants (PVs) in BRCA1/2 genes is infrequent but often associated with aggressive features …
variants (PVs) in BRCA1/2 genes is infrequent but often associated with aggressive features …
[HTML][HTML] HER2-low and HER2-zero in breast cancer between prognosis, prediction and entity
M Schmidt, HA Lehr, K Almstedt - Oncotarget, 2024 - ncbi.nlm.nih.gov
HER2 is a well-established prognostic and predictive factor in breast cancer, which is
associated with a poor prognosis but also offers the chance of improved survival when …
associated with a poor prognosis but also offers the chance of improved survival when …
Unveiling the HER2-low phenomenon: exploring immunohistochemistry and gene expression to characterise HR-positive HER2-negative early breast cancer
Purpose HER2-low breast cancer (BC) is a novel entity with relevant therapeutic
implications, especially in hormone receptor (HR) positive BC. This study examines whether …
implications, especially in hormone receptor (HR) positive BC. This study examines whether …